Clinical Trial

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

Study acronym: IRIS-CKD
Recruiting
View on ClinicalTrials.gov →
Summary
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-03-25; most recent amendment 2026-06-15.
Status change: Not Yet Recruiting → Recruiting 2025-11-04
Trial Details
NCT Number NCT06906627
Lead Sponsor Duke University
Collaborators: Bayer, Boehringer Ingelheim, Eli Lilly and Company
Conditions Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
Enrollment 750 participants
Start Date 2025-10-28
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-16